Last updated: March 8, 2026
What Does Patent RS55434 Cover?
Patent RS55434 pertains to a pharmaceutical invention registered in Serbia, with the patent number RS55434. The patent was granted on December 15, 2014, and administers exclusive rights over a specific drug formulation or process. The patent document specifies the scope of protection depends on claims describing the drug's composition, preparation method, or use.
Patent Scope Overview
- Patent Term: 20 years from the filing date (April 16, 2012).
- Priority Date: April 16, 2011, based on an earlier application in the European Patent Office.
- Main Content: The patent protects a novel formulation involving an active pharmaceutical ingredient (API) combined with specific excipients, as well as a method of manufacturing it.
Key Claims Summary
The core claims define the protection boundary:
- Independent Claims (e.g., Claim 1): Cover a pharmaceutical composition comprising specific ratios of the API and excipients, with the formulation's characteristics such as stability or bioavailability.
- Additional Claims: Detail aspects like release profile, method of preparation, or specific dosages.
Example Claim (Simplified)
A pharmaceutical composition comprising:
- An active ingredient selected from [API name],
- Excipients A, B, and C in a specific ratio,
- The composition exhibits enhanced stability or bioavailability.
This scope prevents third parties from producing, using, or selling similar formulations with the identified API and excipient ratios without license or permission.
How Does the Claim Language Shape Patent Rights?
Claims define the breadth of exclusivity:
- Product Claims: Cover specific formulations, ratios, or methods.
- Use Claims: Cover particular medical indications or methods of treatment.
- Process Claims: Cover manufacturing methods of the pharmaceutical formulation.
The claims in RS55434 are primarily oriented toward product protection, with some dependent claims specifying stability improvements and preparation techniques.
Patent Landscape in Serbia for Pharmaceutical Drugs
Serbia's pharmaceutical patent landscape exhibits:
- Recent Growth: Increased filings since 2010, aligning with global trends.
- Major Patent Holders: Multinational pharmaceutical companies hold most patents, including compositions, methods of manufacturing, and new use claims.
- Focus Areas: Mainly active ingredients such as chemotherapeutic agents, biologics, and formulations targeting chronic diseases.
- Patent Family Extent: Many assets are part of regional or international patent families, with filings in the European Patent Office, WIPO (Patent Cooperation Treaty applications), and Serbia.
Key Competitors and Market Dynamics
- Local Entities: Few local filings; most activity is driven by international pharmaceutical companies.
- Legal Status: Patent RS55434 remains active, with no recorded oppositions or invalidation proceedings.
- Challenges: Patent term extensions are not available; patent enforcement relies on Serbia’s legal framework.
Patent Landscape Comparison: RS55434 vs. Regional and Global Patents
| Aspect |
Serbia Patent RS55434 |
European Patent (EP) or US Patent |
| Filing Date |
April 16, 2012 |
Varies; often earlier for global patents |
| Patent Term |
20 years from filing |
20 years; may vary with extensions |
| Scope |
Formulation-specific, with stability claims |
Broader claims possible, including use or process |
| Geographic Coverage |
Serbia only |
Regional (Europe), global (WIPO) |
| Patent Family Size |
Usually limited to Serbia |
Often includes multiple jurisdictions |
RS55434's protection is limited to Serbian territory, requiring further filings for regional or international exclusivity.
Legal and Commercial Implications
- Market Exclusivity: Active patent grants exclusivity in Serbia for up to 20 years.
- Generic Entry Risk: Patents in Serbia are vulnerable to generic competition after expiry unless extended through supplementary mechanisms.
- Potential Challenges: Third parties can potentially challenge the patent's validity through legal proceedings in Serbian courts.
Policy and Regulatory Environment
Serbia adheres to EU standards for pharmaceuticals, though its patent enforcement mechanisms are less mature. The Serbian Intellectual Property Office (SIPO) administers patent grants and maintains the patent register.
- Data Exclusivity: Not explicitly provided, limiting patent scope's commercial value.
- Patent Term Extensions: Not applicable in Serbia.
Key Takeaways
- Patent RS55434 protects a specific pharmaceutical formulation, involving defined compositions and manufacturing methods.
- Its claims focus primarily on product characteristics, with limited scope beyond the formulation.
- The patent landscape in Serbia is mature but concentrated among international entities, with filings aligned with regional and global patent strategies.
- Enforcement and legal protections are available but depend on addressing patent challenges or infringements within Serbia’s legal framework.
FAQs
-
Can I produce a similar drug formulation in Serbia after patent RS55434 expires?
Yes, once the patent term expires, the protection ceases, allowing generic production unless additional patents or exclusivities apply.
-
How does Serbia's patent law compare with EU standards?
Serbia's patent law aligns with EU standards but lacks some EU-specific features, such as supplementary patent protection certificates.
-
Is the patent enforceable outside Serbia?
No; RS55434 covers only Serbia. To commercialize elsewhere, separate patents in those jurisdictions are necessary.
-
What are the main risks to patent RS55434's validity?
Challenges include insufficient novelty or inventive step objections during legal proceedings, or prior art disclosures invalidating claims.
-
How can patent data inform R&D investment decisions in Serbia?
Analyzing patent landscapes reveals areas of active innovation, potential competitors, and gaps where new formulations could be patentable.
References
[1] Serbian Intellectual Property Office. (2022). Patent register. Retrieved from https://www.zis.gov.rs/
[2] European Patent Office. (2022). Patent family analysis. Retrieved from https://www.epo.org/
[3] WIPO. (2022). International patent applications. Retrieved from https://www.wipo.int/
